Verona Pharma plc (NASDAQ:VRNA) Insider Kathleen A. Rickard Sells 59,720 Shares

Verona Pharma plc (NASDAQ:VRNA – Get Rating) insider Kathleen A. Rickard sold 59,720 shares of the stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $0.54, for a total transaction of $32,248.80. Following the sale, the insider now directly owns 2,546,408 shares in the company, valued at approximately $1,375,060.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

VRNA stock opened at $4.21 on Wednesday. The company’s 50 day moving average price is $5.30 and its 200 day moving average price is $5.44. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.09 and a current ratio of 5.09. Verona Pharma plc has a fifty-two week low of $3.66 and a fifty-two week high of $8.69. The firm has a market capitalization of $254.15 million, a price-to-earnings ratio of -3.14 and a beta of 0.60.

A number of analysts recently weighed in on VRNA shares. Zacks Investment Research upgraded shares of Verona Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research note on Wednesday, April 6th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Verona Pharma in a research note on Tuesday, January 25th.

Several hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new position in Verona Pharma in the fourth quarter valued at approximately $82,000. IPG Investment Advisors LLC purchased a new position in Verona Pharma in the fourth quarter valued at approximately $80,000. Geode Capital Management LLC increased its stake in Verona Pharma by 24.0% in the fourth quarter. Geode Capital Management LLC now owns 13,273 shares of the company’s stock valued at $89,000 after purchasing an additional 2,566 shares during the last quarter. D.A. Davidson & CO. increased its stake in Verona Pharma by 20.0% in the fourth quarter. D.A. Davidson & CO. now owns 48,000 shares of the company’s stock valued at $323,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Lindbrook Capital LLC purchased a new position in Verona Pharma in the fourth quarter valued at approximately $67,000. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Verona Pharma Company Profile (Get Rating)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Further Reading